Sacituzumab govitecan for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage 4 colorectal cancer that cannot be removed with surgery.
- You must have already tried at least three standard chemotherapy drugs (fluoropyrimidine, oxaliplatin, and irinotecan) and they stopped working or caused bad side effects.
- You must not have received irinotecan in the last 6 months.
- Your tumor must not have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).
- You must be at least 18 years old and able to get around (ECOG performance status 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests a new drug called sacituzumab govitecan for people with advanced thyroid cancer that has stopped responding to standard treatments. It may be an option for those with differentiated thyroid cancer (after certain prior therapies) or anaplastic thyroid cancer (first-line or after one prior treatment).
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
This trial tests a drug called IMMU-132 (sacituzumab govitecan) for women with advanced or recurrent ovarian cancer that has come back after platinum-based chemotherapy. The drug targets a protein called TROP-2 found on tumor cells, which may help stop the cancer from growing.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.